The Analyst Verdict: AbbVie In The Eyes Of 5 Experts | Nasdaq

May 17, 2024 · The Analyst Verdict: AbbVie In The Eyes Of 5 Experts. May 17, 2024 — 09:00 am EDT. Written by Benzinga Insights for Benzinga ->. 5 analysts have expressed a variety of …

CouponFollow Extension

$577.91
OFF

The Analyst Verdict: CACI International In The Eyes Of 11 Experts

1 week from now

4 days ago · Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $577.91, with a high estimate of $650.00 and a low estimate of $520.00. …

nasdaq.com

$190.29
OFF

A Glimpse Into The Expert Outlook On AbbVie Through 7 Analysts

1 week from now

Jul 2, 2024 · Analysts have recently evaluated AbbVie and provided 12-month price targets. The average target is $190.29, accompanied by a high estimate of $200.00 and a low estimate of …

nasdaq.com

$105.35
OFF

The Analyst Verdict: Best Buy Co In The Eyes Of 17 Experts - Nasdaq

1 week from now

Nov 8, 2024 · 1. 0. In the assessment of 12-month price targets, analysts unveil insights for Best Buy Co, presenting an average target of $105.35, a high estimate of $123.00, and a low …

nasdaq.com

$17
OFF

The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts

1 week from now

4 days ago · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.5, a high estimate of $21.00, and a low estimate of …

benzinga.com

$252.81
OFF

The Analyst Verdict: Analog Devices In The Eyes Of 21 Experts

1 week from now

Jul 18, 2024 · Analysts have set 12-month price targets for Analog Devices, revealing an average target of $252.81, a high estimate of $285.00, and a low estimate of $210.00.

businessinsider.com

$209.73
OFF

Forecasting The Future: 11 Analyst Projections For AbbVie

1 week from now

Oct 25, 2024 · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $209.73, a high estimate of $225.00, and a low …

nasdaq.com

$29.67
OFF

The Analyst Verdict: Kite Realty Gr Trust In The Eyes Of 6 Experts

1 week from now

5 days ago · Analysts have set 12-month price targets for Kite Realty Gr Trust, revealing an average target of $29.67, a high estimate of $33.00, and a low estimate of $26.00.

benzinga.com

$208.09
OFF

In-Depth Examination Of 11 Analyst Recommendations For …

1 week from now

Oct 7, 2024 · 0. Analysts have recently evaluated AbbVie and provided 12-month price targets. The average target is $208.09, accompanied by a high estimate of $225.00 and a low estimate …

nasdaq.com

$156.33
OFF

The Analyst Verdict: NVIDIA In The Eyes Of 33 Experts - Nasdaq

1 week from now

5 days ago · Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $156.33, with a high estimate of $200.00 and a low estimate of $90.00. …

nasdaq.com

$215
OFF

AbbVie Price Target Lowered To $215 From $226 At Citi - Nasdaq

1 week from now

4 days ago · November 12, 2024 — 06:00 am EST. Written by TheFly for TipRanks ->. Citi analyst Geoff Meacham lowered the firm’s price target on AbbVie (ABBV) to $215 from $226 …

nasdaq.com

$57.67
OFF

The Analyst Verdict: Dow In The Eyes Of 9 Experts | Nasdaq

1 week from now

Sep 13, 2024 · Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $57.67, with a high estimate of $64.00 and a low estimate of …

nasdaq.com

FAQs about The Analyst Verdict: AbbVie In The Eyes Of 5 Experts | Nasdaq Coupon?

How do financial analysts perceive AbbVie?

The perception of AbbVie by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. ...

How do analysts evaluate AbbVie (ABV) stock?

This insight gives a snapshot of analysts' perspectives on the current state of the company. Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of AbbVie compared to the broader market. ...

Does AbbVie have a high debt-to-equity ratio?

Debt Management: With a high debt-to-equity ratio of 10.42, AbbVie faces challenges in effectively managing its debt levels, indicating potential financial strain. Understanding the Relevance of Analyst Ratings ...

Is AbbVie a good company?

Stay up to date on AbbVie analyst ratings. AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. ...

Is AbbVie a good stock to buy?

Debt Management: AbbVie's debt-to-equity ratio is notably higher than the industry average. With a ratio of 9.24, the company relies more heavily on borrowed funds, indicating a higher level of financial risk. Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. ...

Why do analysts'maintain' or 'raise' their stance on AbbVie?

Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AbbVie. ...